ANDA 209710, held by Sandoz. Teriflunomide.
As of Nov 16, 2026, ANDA 209710 (Teriflunomide), held by Sandoz, was first approved by FDA on Jan 3, 2019, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 3, 2019 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Aug 31, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 11, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 4, 2024 | Supplement 5Manufacturing | Approved | None posted |
| Mar 7, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 7, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 19, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 19, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 3, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters